Ignite Creation Date:
2024-05-06 @ 3:33 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04670055
Status:
NOT_YET_RECRUITING
Last Update Posted:
2020-12-17
First Post:
2020-12-09
Brief Title:
A Study of Humanized BCMA-targeted CAR-T Cells Therapy for RefractoryRelapsed Multiple Myeloma
Sponsor:
Zhejiang University
Organization:
Zhejiang University
Study Overview
Official Title:
Clinical Trial for the Safety and Efficacy of Humanized BCMA-targeted CAR-T Cells Therapy for RefractoryRelapsed Multiple Myeloma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2020-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Clinical Trial for the safety and efficacy of humanized BCMA-targeted CAR-T cells therapy for refractoryrelapsed multiple myeloma
Detailed Description:
This is a single arm open-label single-center study This study is indicated for relapsed BCMA multiple myeloma the selections of dose levels and the number of subjects are based on clinical trials of similar foreign products 50 patients will be enrolled for this trial Primary objective is to explore the safety main consideration is dose-related safety
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None